RE: Shareholder action13 Jul 2018 15:09
Theres no confusion about income but we're all aware... "The Company’s business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field". to sell early stage cancer treatments, that was what we invested in, not a biotech firm with commercially available treatments...Will people care about salaries if they announce a £200M deal though? People have lost patience, understandable but that doesn't mean nothing is happening behind the scenes.